Dr. Setsuko Chambers, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
1515 N Campbell Ave
Tucson, AZ 85724
Who else practices at this address →
Pima County includes primary care (34% of residents) and dental (4% of residents) and mental health (14% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Warren Alpert Medical School of Brown University (1980)
- Years since graduation
- 46
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 72
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1980Medical school: Warren Alpert Medical School of Brown University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
AZ license 32571
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Banner - University Medical Center Tucson Campus Tucson, AZ
- Banner-University Medical Center South Campus Tucson, AZ
Medical groups
- Banner-University Medical Group (1,072 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 72
- Services billed
- 396
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 119 | 28 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 110 | 24 |
| Established patient office or other outpatient visit, 30-39 minutes | 27 | 24 |
| Established patient office or other outpatient visit, 20-29 minutes | 25 | 22 |
| New patient office or other outpatient visit, 60-74 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Tucson, AZ | 36 |
| Aprepitant | 31 |
| Prochlorperazine Maleate Other prescribers in Tucson, AZ | 21 |
| Letrozole Other prescribers in Tucson, AZ | 19 |
| Methylprednisolone Other prescribers in Tucson, AZ | 19 |
| Penicillin V Potassium Other prescribers in Tucson, AZ | 17 |
| Anastrozole Other prescribers in Tucson, AZ | 14 |
| Dexamethasone Other prescribers in Tucson, AZ | 13 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Tucson, AZ | 13 |
| Levothyroxine Sodium Other prescribers in Tucson, AZ | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $66,085 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Genmab U.S., Inc. - Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie Inc. · Active, not recruiting · NCT05456685 - A phase 3, randomized, double-blind, placebo-controlled, multicenter s
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.